Back to AMGN
Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
2 competitors in Temporomandibular Disorder
View Full LandscapeDrug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA7/26/2018
Aimovig
Aimovig is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month when initiating treatment with Aimovig.
View on EMADrug Science
Mechanism of action & safety profile
Related Pipeline
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
